Group 1 - Corning Pharmaceutical-B (09966) saw a stock increase of over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD [1] - The company announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD, as part of a broader authorization to repurchase shares up to a maximum of 20 million HKD [1] - The European Society for Medical Oncology (ESMO) conference will take place from October 17 to 21 in Berlin, with 23 research studies from China, including key studies like Corning's KN026, being presented [1]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 16, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 192 million [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.44 million [2] - Yun Gongchang (N23027) repurchased 2.01 million shares for 8.19 million [2] Group 2: Cumulative Buyback Data - Xiaomi Group-W has a cumulative buyback of 16.59 million shares, representing 0.060% of total share capital [2] - Mengniu Dairy has a cumulative buyback of 17.32 million shares, representing 0.443% of total share capital [2] - Yun Gongchang has a cumulative buyback of 20.62 million shares, representing 4.483% of total share capital [2] Group 3: Other Notable Buybacks - Lianyi Rong Technology-W (09959) repurchased 2.39 million shares for 7.48 million, with a cumulative total of 60.47 million shares, representing 2.830% of total share capital [2] - Kangning Jiere Pharmaceutical-B (09966) repurchased 400,000 shares for 5.48 million, with a cumulative total of 801,000 shares, representing 0.083% of total share capital [2] - Guisheng Tongqiao-B (02190) repurchased 50,000 shares for 1.24 million, with a cumulative total of 330,350 shares, representing 1.009% of total share capital [2]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) repurchased 400,000 shares on October 16, 2025, at a total cost of HKD 5.483 million, indicating a strategic move to enhance shareholder value [1][2]. Group 1: Share Buyback Details - The company repurchased shares at prices ranging from HKD 13.520 to HKD 13.820 per share [1]. - The closing price on the day of the buyback was HKD 13.700, reflecting a 2.54% increase in share price [1]. - The total trading volume for the day was HKD 35.6313 million [1]. Group 2: Year-to-Date Buyback Summary - Year-to-date, the company has conducted three buyback transactions, totaling 801,000 shares repurchased [2]. - The cumulative amount spent on buybacks this year is HKD 10.9358 million [2]. - Detailed buyback transactions include: - October 16: 400,000 shares at a maximum price of HKD 13.820 and a minimum price of HKD 13.520, costing HKD 5.483 million [2]. - October 14: 293,000 shares at a maximum price of HKD 13.830 and a minimum price of HKD 13.030, costing HKD 3.9669 million [2]. - October 13: 108,000 shares at a maximum price of HKD 13.800 and a minimum price of HKD 13.690, costing HKD 1.4860 million [2].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback plan, indicating confidence in its financial position and future growth potential [1] Summary by Category Company Actions - The company plans to repurchase 400,000 shares at a total cost of HKD 5.483 million, scheduled for October 16, 2025 [1]

康宁杰瑞制药-B(09966)发布公告，于2025年10月16日，该公司斥资548.3万港元回购40万股。 ...

格隆汇10月16日丨康宁杰瑞制药-B(09966.HK)公告，10月16日耗资548.3万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年10月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].

Core Viewpoint - 康宁杰瑞制药-B (09966) announced a share buyback plan, investing HKD 3.9669 million to repurchase 293,000 shares [1] Group 1 - The company plans to execute the buyback on October 14, 2025 [1] - The total amount allocated for the buyback is HKD 3.9669 million [1] - The number of shares to be repurchased is 293,000 [1]